To print this article, all you need is to be registered or login on Mondaq.com.
The U.S. Patent and Trademark Office s Patent Trial and
Appeal Board (PTAB) recently grappled with the admission into
evidence of expert deposition testimony that was presumably harmful
to the petitioner in an
inter partes review
(IPR), and barred the testimony from coming into evidence.
In
Axonics Modulation Technologies, Inc. v. Medtronic, Inc.,
Cases IPR2020-00678, IPR2020-00680, IPR2020-00712, Paper 22 (April
9, 2021), the petitioner elected to depose patent owner s
expert, but then declined to submit the transcript as an exhibit to
the petitioner reply. The patent owner then attempted to
Abbott Laboratories (NYSE:ABT), (AMTI) - The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu s Positive COVID-19 Data
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Posted on 103
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has acquired privately-held Contura Ltd. and its flagship product, Bulkamid, a best-in-class urethral bulking agent for women with stress urinary incontinence (SUI).
Axonics acquired London-based Contura Ltd. for total consideration of $200 million in cash and stock, and a potential future milestone of $35 million.
SUI is a large and highly underpenetrated market with a prevalence of an estimated 20 million women in the U.S. alone. It is a condition that afflicts women of all ages, with childbirth as one of the main contributing factors. SUI is caused by weakness in the pelvic floor, preventing the urethra from closing fully when sudden pressure is put o